Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3mc Syndrome 3 C0796032
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3mc Syndrome 3 for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3mc Syndrome 3 C0796032
Another rare variant of 3MC syndromes, a genetic disorder causing developmental differences and facial features. Care involves various specialists addressing individual needs.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3mc Syndrome 3 C0796032
0-0
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3mc Syndrome 3 C0796032
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3mc Syndrome 3 C0796032
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3mc Syndrome 3 C0796032
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3mc Syndrome 3 C0796032
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3mc Syndrome 3 C0796032
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3mc-syndrome-3-C0796032 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3mc Syndrome 3 C0796032 | Discriminating power |
|---|---|---|---|
| Neurologic features | Developmental delay, seizures, and movement difficulty are described. | Developmental differences are described; seizures are not established here. | Moderate |
| Facial appearance | Characteristic facial features are not established by the supplied description. | Distinctive facial features are a reported part of the syndrome. | Moderate |
| Onset | Reported onset is in early childhood, from birth to age 5. | Reported onset is congenital, at birth. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early neurologic presentation
Seizures, developmental delay, or movement difficulty suggest evaluation for a serine-related metabolic disorder.
Moderate
Suspected metabolic disease
The described mechanism is impaired serine production rather than a primarily structural congenital syndrome.
Moderate
Treatment planning
Reported management may include serine supplementation and anticonvulsants when clinically indicated.
Low
Choose 3mc Syndrome 3 C0796032 when
Congenital dysmorphic pattern
Facial features with developmental differences fit the supplied description of 3MC syndrome 3.
Moderate
Multispecialty congenital care
Care is described as individualized and coordinated across relevant specialists.
Moderate
No established metabolic clue
Choose this only after clinical assessment; absence of seizures does not exclude either condition.
Low
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3mc Syndrome 3 C0796032 | Interpretation |
|---|---|---|---|
| Amino acid studies | May be used to assess serine status; no cutoff is supplied. | No characteristic amino acid abnormality is established here. | An abnormal result is not a diagnosis and needs specialist review. |
| Genetic testing | May support the metabolic diagnosis when clinically indicated. | May support a 3MC-related genetic diagnosis when indicated. | Gene selection and interpretation require a genetics clinician. |
| Clinical dysmorphology exam | No defining facial pattern is established in the source. | Facial features are a key described finding. | Examination findings should be correlated with genetics and development. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- A severe chronic neurologic course is described, but individual outcome is not established.
- Factors
- Seizure control, developmental support, and response to indicated serine supplementation may matter.
3mc Syndrome 3 C0796032
- Outcome
- A moderate chronic congenital course is described, with substantial individual variation.
- Factors
- The pattern of developmental and facial or structural needs may influence support.
Time frame: Both are described as chronic; exact long-term outcomes are not supplied.
Early recognition, specialist care, and individualized developmental support are relevant.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | Seizures are a described neurologic feature. Seizure risk is not established by the supplied data. Anticonvulsant use depends on individual clinical assessment. |
| Developmental impairment | Developmental delay is described and may be severe. Developmental differences are described, with moderate overall severity. Support needs vary and are not predictable from these labels alone. |
| Movement difficulty | Movement difficulties are specifically described. Movement complications are not established here. Functional assessment should guide therapy. |
Patient education highlights
- HighSpecialist confirmation
Both are rare; diagnosis and management should be confirmed by appropriate specialists.
- HighIndividualized care
Reported treatments and supports depend on symptoms and should not be generalized.
- MediumMonitoring
Development, seizures, movement, and congenital needs may require ongoing review.